Related Experiment Video
Updated: Aug 5, 2026
07:58
Data Processing Methods for 3D Seismic Imaging of Subsurface Volcanoes: Applications to the Tarim Flood Basalt
Published on: August 7, 2017
Methodological considerations in the interpretation of ASCENT-03
Francesca Poggio1, Daniele Generali2
1Clinica di Oncologia Medica, AOM - IRCCS Ospedale Policlinico San Martino, Genova, Italy.
European Journal of Cancer (Oxford, England : 1990)
|July 28, 2026
Summary
Sacituzumab govitecan improved progression-free survival in previously untreated metastatic triple-negative breast cancer (mTNBC) patients ineligible for PD-(L)1 inhibitors. Further overall survival data are needed to confirm its role as a first-line standard of care for mTNBC.
Area of Science:
- Oncology
- Medical Oncology
- Clinical Trials
Background:
- Metastatic triple-negative breast cancer (mTNBC) without PD-(L)1 inhibitor eligibility presents a significant unmet need.
- A substantial proportion of mTNBC patients have tumors with PD-L1 CPS < 10.
- Many mTNBC patients do not receive subsequent lines of therapy.
Purpose of the Study:
- To evaluate the efficacy of sacituzumab govitecan (SG) compared to chemotherapy as a first-line treatment for patients with previously untreated metastatic triple-negative breast cancer (mTNBC) ineligible for PD-(L)1 inhibitors.
Main Methods:
- The ASCENT-03 trial compared sacituzumab govitecan (SG) with chemotherapy in this patient population.
- Progression-free survival (PFS) was a primary endpoint.
Main Results:
- Sacituzumab govitecan demonstrated a statistically significant improvement in progression-free survival (PFS) compared to chemotherapy.
- This benefit was observed in a patient group with limited treatment options.
Conclusions:
- Sacituzumab govitecan shows promise as a first-line treatment for previously untreated mTNBC patients ineligible for PD-(L)1 inhibitors.
- Mature, crossover-adjusted overall survival analyses are required to establish SG as a definitive first-line standard of care.
